Small molecule inhibitors in children with malignant gliomas

Pediatric Blood and Cancer

Volumn 53, Issue 3, 2009, Pages 312-317

  Herrington, Betty ^a   Kieran, Mark W ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Cell signaling; Glioma; Small molecule inhibitor; Targeted therapy

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BB 251; BEVACIZUMAB; CEDIRANIB; CILENGITIDE; DASATINIB; ENZASTAURIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; LAPATINIB; LONAFARNIB; MARIMASTAT; OBLIMERSEN; PAZOPANIB; PD 00325901; PX 866; RAPAMYCIN; RAS PROTEIN; ROMIDEPSIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VANDETANIB; VATALANIB; VORINOSTAT; WORTMANNIN;

ANGIOGENESIS; APOPTOSIS; CANCER INHIBITION; CANCER INVASION; CANCER STEM CELL; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; DRUG MECHANISM; GLIOBLASTOMA; HUMAN; LIGAND BINDING; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CHILD; GLIOMA; HISTONE DEACETYLASES; HUMANS; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 67650397808     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21950     Document Type: Review

References (45)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO classification of tumors of the central nervous system, 4th edition. IARC Press; Lyon: 2007.
2. Pytel P. Spectrum of pediatric gliomas: Implications for the development of future therapies. Expert Rev Anticancer Ther 2007; 7:S51-S60.
3. Poussaint TY, Rodriguez D. Advanced neuroimaging of pediatric brain tumors: MR diffusion, MR perfusion, and MR spectroscopy. Neuroimaging Clin N Am 2006;16:169-192, ix.
4. Finlay JL, Boyett JM, Yates AJ, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J Clin Oncol 1995;13:112-123.
5. Geyer JR, Finlay JL, Boyett JM, et al. Survival of infants with malignant astrocytomas. A Report from the Childrens Cancer Group. Cancer 1995;75:1045-1050.
6. Sanders RP, Kocak M, Burger PC, et al. High-grade astrocytoma in very young children. Pediatr Blood Cancer 2007;49:888-893. (Pubitemid 350022440)
7. Broniscer A, Gajjar A. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: Two challenges for the pediatric oncologist. Oncologist 2004;9:197-206. (Pubitemid 38452119)
8. Heuer GG, Jackson EM, Magge SN. et al. Surgical management of pediatric brain tumors. Expert Rev Anticancer Ther 2007;7:S61-S68.
9. Stieber VW, Mehta MP. Advances in radiation therapy for brain tumors. Neurol Clin 2007;25:1005-1033, ix.
10. Stupp R, Hegi ME, Gilbert MR, et al. Chemoradiotherapy in malignant glioma: Standard of care and future directions. J Clin Oncol 2007;25:4127-4136. (Pubitemid 47492957)
11. Nicholas MK. Glioblastoma multiforme: Evidence-based approach to therapy. Expert Rev Anticancer Ther 2007;7:S23-S27.
12. Perry J, Laperriere N, Zuraw L, et al. Adjuvant chemotherapy for adults with malignant glioma: A systematic review. Can J Neurol Sci 2007;34:402-410. (Pubitemid 350248266)
13. Sposto R, Ertel IJ, Jenkin RD, et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: Results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol 1989;7:165-177. (Pubitemid 19182070)
14. Wolff JE, Gnekow AK, Kortmann RD, et al. Preradiation chemotherapy for pediatric patients with high-grade glioma. Cancer 2002;94:264-271. (Pubitemid 34049068)
15. Yang SH, Hong YK, Yoon SC, et al. Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma. Oncol Rep 2007;17: 1359-1364.
16. Pollack IF, Hamilton RL, SobolRW, et al. O6-methylguanine-DNA methyltransferase exressin strongly correlates with outcome in childhood malignant gliomas: Results from the CCG-945 Cohort. J Clin Oncol 2006;24:3431-3437.
17. Haque T, Faury D, Albrecht S, et al. Gene expression profiling from formalin-fixed paraffin-embedded tumors of pediatric glioblastoma. Clin Cancer Res 2007;13:6284-6292. (Pubitemid 350075016)
18. Gallia GL, Rand V, Siu IM, et al. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res 2006;4:709-714. (Pubitemid 44683311)
19. Tabori U, Dome JS. Telomere biology of pediatric cancer. Cancer Invest 2007;25:197-208.
20. Ganigi PM, Santosh V, Anandh B, et al. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: A study of 54 patients. Pediatr Neurosurg 2005;41:292-299. (Pubitemid 41636332)
21. de Groot JF, Gilbert MR. New molecular targets in malignant gliomas. Curr Opin Neurol 2007;20:712-718. (Pubitemid 350085016)
22. van den Bent DMJ. Molecular targeted therapies and chemotherapy in malignant gliomas. Curr Opin Oncol 2007;19:598-605.
23. Thaimattam R, Banerjee R, Miglani R, et al. Protein kinase inhibitors: Structural insights into selectivity. Curr Pharm Des 2007;13:2751-2765. (Pubitemid 350130972)
24. Leary A, Johnston SR. Small molecule signal transduction inhibitors for the treatment of solid tumors. Cancer Invest 2007; 25:347-365. (Pubitemid 47185077)
25. Penas-Prado M, Gilbert MR. Molecularly targeted therapies for malignant gliomas: Advances and challenges. Expert Rev Anticancer Ther 2007;7:641-661. (Pubitemid 46805561)
26. KieranMW. Anti-angiogenic therapy in pediatric neuro-oncology. J Neurooncol 2005;75:327-334.
27. Sathornsumetee S, Rich JN. Antiangiogenic therapy in malignant glioma: Promise and challenge. Curr Pharm Des 2007;13:3545-3558. (Pubitemid 350238925)
28. Lukas RV, Boire A, Nicholas MK. Emerging therapies for malignant glioma. Expert Rev Anticancer Ther 2007;7:S29-S36.
29. Kesari S, Ramakrishna N, Sauvageot C. et al. Targeted molecular therapy of malignant gliomas. Curr Oncol Rep 2006;8:58-70. (Pubitemid 43154265)
30. Newton HB. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors. Curr Opin Invest Drugs 2007;8:1009-1021.
31. Sandsmark DK, Pelletier C,Weber JD, et al. Mammalian target of rapamycin: Master regulator of cell growth in the nervous system. Histol Histopathol 2007;22:895-903.
32. Gerstner ER, Duda DG, di Tomaso E, et al. Antiangiogenic agents for the treatment of glioblastoma. Expert Opin Invest Drugs 2007;16:1895-1908.
33. Castellino RC, Durden DL. Mechanisms of Disease: The PI3KAkt-PTEN signaling node - An intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol 2007;3:682-693.
34. Wang D, Anderson JC, Gladson CL. The role of the extracellular matrix in angiogenesis in malignant glioma tumors. Brain Pathol 2005;15:318-326. (Pubitemid 41677431)
35. Ziegler DS, Kung AL, KieranMW. Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol 2008;26:493-500.
36. Lee daY, Gutmann DH. Cancer stem cells and brain tumors: Uprooting the bad seeds. Expert Rev Anticancer Ther 2007;7: 1581-1590.
37. Cavaliere R, Wen PY, Schiff D. Novel therapies for malignant gliomas. Neurol Clin 2007;25:1141-1171.
38. KieranMW, Packer RJ, Onar A, et al. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: A Pediatric Brain Tumor Consortium Study. J Clin Oncol 2007;25:3137-3143. (Pubitemid 47218063)
39. Haas-Kogan DA, Banerjee A, Kocak M, et al. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Neuro Oncol 2008;10:341-347.
40. Fouladi M, Nicholson HS, Zhou T, et al. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/ primitive neuroectodermal tumor, or brainstem glioma: A Children's Oncology Group study. Cancer 2007;110:2535-2541. (Pubitemid 350174941)
41. Amit I, Wides R, Yarden Y. Evolvable signaling networks of receptor tyrosine kinases: Relevance of robustness to malignancy and to cancer therapy. Mol Syst Biol 2007;3:151. (Pubitemid 350223359)
42. Mishani E, Abourbeh G. Cancer molecular imaging: Radionuclidebased biomarkers of the epidermal growth factor receptor (EGFR). Curr Top Med Chem 2007;7:1755-1772. (Pubitemid 350130995)
43. Hammoud DA, Hoffman JM, Pomper MG. Molecular neuroimaging: From conventional to emerging techniques. Radiology 2007;245:21-42.
44. Schaller BJ, Modo M, Buchfelder M. Molecular imaging of brain tumors: A bridge between clinical and molecular medicine? Mol Imaging Biol 2007;9:60-71.
45. Herholz K, Coope D, Jackson A. Metabolic and molecular imaging in neuro-oncology. Lancet Neurol 2007;6:711-724.